Loading…
Based on limited metadata, TeraPharm received an FDA Warning Letter issued on October 9, 2018, regarding drug products. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the issuing office is not identified in the metadata provided. To understand the actual compliance issues and required corrective actions, review of the complete Warning Letter document would be necessary.